http://sgc.anlis.gob.ar/handle/123456789/25 2026-04-09T11:48:30Z 2026-04-09T11:48:30Z Perrone, Alina E. Pinillo, Mariana Rial, Marcela Silvina Fernandez, Marisa Milduberger, Natalia González, Carolina Bustos, Patricia L. Fichera, Laura E. Laucella, Susana A. Albareda, María Cecilia Bua, Jacqueline http://sgc.anlis.gob.ar/handle/123456789/2732 2026-03-19T15:10:23Z 2023-07-25T00:00:00Z

Title: Trypanosoma cruzi Secreted Cyclophilin TcCyP19 as an Early Marker for Trypanocidal Treatment Efficiency Authors: Perrone, Alina E.; Pinillo, Mariana; Rial, Marcela Silvina; Fernandez, Marisa; Milduberger, Natalia; González, Carolina; Bustos, Patricia L.; Fichera, Laura E.; Laucella, Susana A.; Albareda, María Cecilia; Bua, Jacqueline Abstract: Cyclophilins (CyPs) are a family of enzymes involved in protein folding. Trypanosoma cruzi, the causative agent of Chagas disease, has a 19-kDa cyclophilin, TcCyP19, that was found to be secreted in parasite stages of the CL Brener clone and recognized by sera from T. cruzi-infected mice and patients. The levels of specific antibodies against TcCyP19 in T. cruzi-infected mice and subjects before and after drug treatment were measured by an in-house enzyme linked immunosorbent assay (ELISA). Mice in the acute and chronic phase of infection, with successful trypanocidal treatments, showed significantly lower anti-TcCyP19 antibody levels than untreated mice. In children and adults chronically infected with T. cruzi, a significant decrease in the anti-TcCyP19 titers was observed after 12 months of etiological treatment. This decrease was maintained in adult chronic patients followed-up 30–38 months post-treatment. These results encourage further studies on TcCyP19 as an early biomarker of trypanocidal treatment efficiency.

2023-07-25T00:00:00Z Viegas Andrade, Monica de Souza Noronha, Kenya Valeria Micaela de Souza, Aline Abreu Julião. Nayara Motta-Santos, André Soares Franco Braga, Paulo Estevão Bracarense, Henrique Alves do Santos, André Batista Ramos Nascimento, Bruno Machado,Ísis Eloah Martins-Melo, Francisco Rogerlândio Molina, Israel Perel, Pablo Geissbühler, Yvonne Demacq, Caroline Castro Jaramillo, Hector Eduardo Echeverria, Luis E Principato, Mario Bruno Aguilera Mora, Luisa Fernanda Fernandez, Marisa Nina Calisaya, Jhonatan Jhimmy Pinho Ribeiro, Antonio Luiz http://sgc.anlis.gob.ar/handle/123456789/2712 2026-02-25T16:34:19Z 2026-02-01T00:00:00Z

Title: Economic burden of Chagas disease in Latin American countries: a population-based cost-of-illness analysis from the RAISE study Authors: Viegas Andrade, Monica; de Souza Noronha, Kenya Valeria Micaela; de Souza, Aline; Abreu Julião. Nayara; Motta-Santos, André Soares; Franco Braga, Paulo Estevão; Bracarense, Henrique; Alves do Santos, André Batista; Ramos Nascimento, Bruno; Machado,Ísis Eloah; Martins-Melo, Francisco Rogerlândio; Molina, Israel; Perel, Pablo; Geissbühler, Yvonne; Demacq, Caroline; Castro Jaramillo, Hector Eduardo; Echeverria, Luis E; Principato, Mario Bruno; Aguilera Mora, Luisa Fernanda; Fernandez, Marisa; Nina Calisaya, Jhonatan Jhimmy; Pinho Ribeiro, Antonio Luiz Abstract: Background Chagas disease (ChD) remains a public health concern in Latin America. Despite a decline in overall prevalence, the chronic symptomatic forms still impose a substantial epidemiological and economic burden. This study undertakes a comprehensive, population-based cost analysis of chronic Chagas disease (CCD) from a societal perspective in seven endemic Latin American countries for 2010 and 2023. Methods A Markov model with one-year cycles and six states was employed. Direct medical and indirect costs, converted to 2024 purchasing power parity US dollars, were estimated using prevalence data from the Global Burden of Disease Study 2023. Based on a previous Brazilian Markov model, parameters were adjusted using healthcare coverage and per capita health expenditure ratios for each country, further validated by national experts. Findings In 2010, Brazil (US$252 billion) and Argentina (US$164 billion) had the highest lifetime burdens. As a percentage of annual Gross Domestic Product, Bolivia (0⋅9%) and Argentina (0⋅8%) were most affected. CCD accounted for 6% of total health expenditures in both countries. Between 2010 and 2023, most countries experienced a decline in economic burden due to decreased CCD prevalence, despite an increased proportion of patients with cardiac conditions, reflecting population aging and disease progression

2026-02-01T00:00:00Z Agüero, Facundo A Maglioco, Andrea Valacco, María Pía Juárez Valdez, Alejandra Yaqueline Roldán, Emilio Paulino, M Fuchs, Alicia G http://sgc.anlis.gob.ar/handle/123456789/2705 2026-02-05T18:16:11Z 2025-10-31T00:00:00Z

Title: First In Silico Study of Two Echinococcus granulosus Glyceraldehyde-3-Phosphate Dehydrogenase Isoenzymes Recognized by Liver Cystic Echinococcosis Human Sera Authors: Agüero, Facundo A; Maglioco, Andrea; Valacco, María Pía; Juárez Valdez, Alejandra Yaqueline; Roldán, Emilio; Paulino, M; Fuchs, Alicia G Abstract: Cystic echinococcosis (CE) is an endemic zoonotic disease caused by Echinococcus granulosus, which forms cysts in ungulates’ intermediate hosts. Humans are accidental hosts, and CE affects more than one million people worldwide. Imaging remains the diagnostic gold standard, outperforming serological methods. This study presents an in silico analysis of two glyceraldehyde-3-phosphate dehydrogenase (GAPDH) isoenzymes from E. granulosus (EgGAPDH), isolated from a parasite cell line (EGPE). EgGAPDHs were recognized by sera from CE patients, identified through LC-MS/MS and PCR of metacestodes from cattle liver. One isoenzyme is intracellular (IC) (UniProt: W6UJ19), and the other is extracellular (EC) (UniProt: W6V1T8). GAPDH is involved in host–parasite interactions and metabolic processes. We characterized the physicochemical properties; linear epitopes (LEPs); and amino acid domains of EgGAPDH, its hosts, and other parasites. W6UJ19 emerged as the most promising isoenzyme as a marker of infection. Molecular dynamics simulations of isoenzymes, performed in the presence or absence of two bisphosphonates (BPs), revealed how drug binding alters conformational epitopes (CEPs) and suggested that W6UJ19 is more responsive to BP modulation. Binding affinity analysis using the MMPBSA method revealed that etidronate (EHDP) binds EgGAPDH with greater affinity than phosphate (Pi) and alendronate (AL), in the following order: EHDP > Pi > AL.

2025-10-31T00:00:00Z Garimano, Nicolas Frias, Taís Aguayo González Maglio, Daniel H http://sgc.anlis.gob.ar/handle/123456789/2685 2025-11-12T14:47:35Z 2025-04-11T00:00:00Z

Title: Beyond ultraviolet radiation: Immune system modulation through skin exposure to visible light and infrared radiation Authors: Garimano, Nicolas; Frias, Taís Aguayo; González Maglio, Daniel H Abstract: Sunlight profoundly affects skin health when it is exposed. After acute exposure, a robust inflammatory response is initiated locally. Moreover, chronic exposures lead to carcinogenesis and photoaging. Local and systemic immunosuppression is also triggered after skin irradiation, affecting adaptive immune responses. These effects are mainly produced by the ultraviolet radiation contained in sunlight and were extensively described and reviewed. However, using UV filters during sunbathing and outdoor activities may allow visible light (VL) wavelengths and infrared radiation (IRR) to reach skin cells. Additionally, the employment of therapeutic VL and IR-emitting lasers and LED devices is increasing for various skin conditions. This literature review aims to present current knowledge on the effects of VL and IRR modulating the skin and systemic immune system. These modulations impact healthy skin and can modify immune responses to diverse stimuli in various cell types. According to the wavelength and the dose, VL and IRR increase the production of reactive oxygen species and promote faster wound healing. Moreover, they modulate inflammatory mediators, such as several cytokines and prostaglandins. However, skin exposure to VL can also affect adaptive immune responses. The study of VL and IRR effects on immunity would promote new uses for phototherapy and may establish the need for new strategies in photoprotection.

2025-04-11T00:00:00Z